Cannabis-Related Problems, Adverse Events, Clinical Experiences and Barriers to Intervening: Perspectives of Health Care Providers in Washington State
- 30 March 2026
- journal article
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 852-863
Abstract
Background: Patients presenting with cannabis-related adverse events (AEs) and other problems are becoming increasingly prevalent in health care settings across the U.S. and Canada, increasing the burden on providers and health systems. Understanding how healthcare providers perceive and respond to cannabis AEs can inform medical training and clinical practices, health policy, and systems-level interventions. Methods: The study was conducted in Washington State, a U.S. state that legalized cannabis for non-medical use in 2012. Health care providers were invited to complete an anonymous online survey between December 2024 and March 2025, eliciting frequency and seriousness of various cannabis-related AEs, related clinical practices and procedures, knowledge and confidence addressing such problems, level of concern, and barriers and facilitators to identifying and intervening in such events. Results: Three hundred and eighty-eight valid survey responses were included in the analysis. Most respondents were mdical doctors and worked in hospitals or primary care clinics. Thirty-five percent of respondents reported seeing cannabis AEs and use-related problems frequently (at least 2-3 times a month) in clinical practice. Severe cyclic vomiting was most common (70% reported it ever occurred) and was second to psychosis as “most serious” (33% and 34%). While most providers saw screening and intervening as important (90%), only 39.1% reported universally screening for cannabis and identified many barriers to intervening. Conclusion: Health care providers in a legal cannabis state have encountered AEs and other complications related to cannabis use, and many are concerned about their frequency and severity. According to study participants, expanding access to clinical guidelines, validated tools, referral pathways, and specialized training may enhance their willingness and capacity to screen and intervene effectively.Keywords
Funding Information
- Washington State Legislature (ESSB 5187)
- University of Washington
This publication has 54 references indexed in Scilit:
- Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis PoisoningJAMA Psychiatry, 2025
- Cannabis, cannabinoids and health: a review of evidence on risks and medical benefitsEuropean Archives of Psychiatry and Clinical Neuroscience, 2024
- Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without PsychosisJAMA Psychiatry, 2023
- Provider Intentions to Implement Cannabis Use Intervention in First Episode Psychosis TreatmentCommunity Mental Health Journal, 2023
- A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabisInternational Journal of Clinical Pharmacy, 2022
- Growth in Recreational Cannabis Markets and Burden on Emergency DepartmentsJAMA Network Open, 2021
- The clinical implications of legalizing marijuana: Are physician and non-physician providers prepared?Addictive Behaviors, 2017
- Management of cannabis use during pregnancy: an assessment of healthcare professionals' practicesPharmacoepidemiology and Drug Safety, 2011
- Swiss Psychiatrists Beliefs and Attitudes about Cannabis Risks in Psychiatric Patients: Ideologically Determined or Evidence-based?Community Mental Health Journal, 2007
- Effects of Cannabis sativa (marihuana) on maze performance of the ratPsychopharmacology, 1965